Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.
Breanna Taylor, PharmD, BCOP
Advertisement
Articles by Breanna Taylor, PharmD, BCOP
Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
FDA Approves Gazyva for Active Lupus Nephritis
3
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
4
Walgreens Strengthens Vaccine Access Through Digital Tools, Pharmacist Education
5
